Search

everythinglearnresearchcommunity

for

Search:↓

Systematic end-of-trial biopsies are the most reliable way to assess outcomes.

Combination therapy for BPH is more effective in certain men but may not be cost-effective due to minimal impact and potential side effects.

Finasteride lowers PSA levels and prostate size, requiring adjusted PSA interpretation for accurate cancer screening.

A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.

Testosterone increases muscle mass regardless of DHT conversion blocking.

Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.

Urinary PSA could be an early marker for enlarged prostate.

Finasteride improves urinary symptoms and quality of life in BPH patients, especially with larger prostate size.

Combination therapy with Finasteride is more effective than alpha-blocker alone for BPH symptoms in small prostate volume.

Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.

Biofeedback treatment for dysfunctional voiding in adults showed no symptom improvement.

Methotrexate treatment for rheumatoid arthritis has a serious infection rate of about two per 100 patient-years.

Stopping finasteride improves sperm quality but not semen volume in young men.

There is no link between hair loss and prostate enlargement.

Early hair loss in men could be a sign of non-cancerous prostate enlargement, and treating hair loss early might help prevent prostate issues later.

Hair loss can be an early sign of prostate enlargement.

People with early-onset hair loss (AGA) have a higher risk of heart disease, metabolic syndrome, and prostate enlargement.

Cervi Parvum Cornu complex improved urinary symptoms in men without major side effects.

Finasteride effectively reduces prostate size in dogs with benign prostatic hyperplasia at a low, safe dose.

Finasteride reduces prostate size and symptoms with few side effects.

Large prostates link to more hair loss.

Finasteride helps reduce prostate size and symptoms in BPH but is less effective than terazosin and works best for larger prostates.

Finasteride treatment increased blood volume and reduced vessel leakiness in beagle prostates.

Large prostate patients more likely to have hair loss.

CEC levels may be a useful marker for predicting prostate cancer progression.

Certain gene variants may raise the risk of prostate enlargement, but taking NSAIDs could reduce this risk.

Using a single PSA level to decide on a prostate biopsy is not effective; a more personalized approach considering various factors is recommended.

Cone beam computed tomography can allow for smaller safety margins around the target area in prostate cancer radiation treatment if used for ongoing treatment checks.

Obesity is linked to more severe lower urinary tract symptoms.

PSA levels help determine prostate size and guide treatment choices for benign prostatic hyperplasia.